Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.

The Prostate - 1 May 2015

Wu Gang, Huang Shengsong, Nastiuk Kent L, Li Jinliang, Gu Jun, Wu Ming, Zhang Qimin, Lin Hanqing, Wu Denglong

Abstract excerpt

BACKGROUND: 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1), which is a rate-limiting enzyme that catalyzes the conversion of adrenal-derived steroid dehydroepiandrosterone to dihydrotestosterone (DHT), may be a promising target for treating castration-resistant prostate cancer (CRPC). METHODS: From 2004 to 2011, a total of 103 consecutive patients presenting with advanced prostate cancer were included in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to Kallikreins
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multienzyme Complexes

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Prostatic Neoplasms, Castration-Resistant

Share to Steroid Isomerases

Source

Open in PubMed Open full text

Identifiers

PMID: 25731771
DOI: 10.1002/pros.22967
PMCID: PMC4912133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.PMID 25731771Read ↗

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Semantic proximity Read ↗

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and BeyondSemantic proximity Read ↗

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.Semantic proximity Read ↗

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.Semantic proximity Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.